Localization of the ezrin binding epitope for glycated proteins

Annals of the New York Academy of Sciences

Volumn 1043, Issue , 2005, Pages 617-624

  McRobert, E Anne ^a,c   Tikoo, Anjali ^a   Gallicchio, Marisa A ^a   Cooper, Mark E ^b   Bach, Leon A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Advanced glycation end products (AGEs); Diabetes; ERM; Ezrin; Moesin; Radixin

Indexed keywords

ACTIN; ADVANCED GLYCATION END PRODUCT; BINDING PROTEIN; EPITOPE; EZRIN; LIGAND; MOESIN; RADIXIN;

ACTIN FILAMENT; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL MEMBRANE; CELL MOTILITY; CELL SHAPE; CELL STRAIN; CONFERENCE PAPER; CYTOSKELETON; DIABETES MELLITUS; KIDNEY PROXIMAL TUBULE; LIGAND BINDING; NONHUMAN; PROTEIN CROSS LINKING; PROTEIN DOMAIN; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 23744495840     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1333.070     Document Type: Conference Paper

References (47)

1. WILDING, J. & G. WILLIAMS. 2002. Diabetes mellitus and disorders of lipid and intermediary metabolism. In Textbook of Medicine. R.L. Souhami & J. Moxham, Eds.: 984-999. Churchill Livingstone.
2. JERUMS, G. et al. 2003. Evolving concepts in advanced glycation, diabetic nephropathy and diabetic vascular disease. Arch. Biochem. Biophys. 419: 55-62.
3. BROWNLEE, M. 1994. Glycation and diabetic complications. Diabetes 43: 836-841.
4. BEISSWENGER, P.J. et al. 1995. Formation of immunochemical AGEs precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 44: 824-829.
5. VLASSARA, H. et al. 1994. AGEs induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci. USA 91: 11704-11708.
6. FORBES, J.M. et al. 2001. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44: 108-114.
7. WAUTIER, J.L. et al. 1996. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest. 97: 238-243.
8. HAMMES, H. et al. 1991. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Natl. Acad. Sci. USA 88: 11555-11558.
9. KIHARA, M. et al. 1991. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc. Natl. Acad. Sci. USA 88: 6107-6111.
10. RUMBLE, J.R. et al. 1997. Vascular hypertrophy in experimental diabetes: role of advanced glycation end products. J. Clin. Invest. 99: 1016-1027.
11. NEEPER, M. et al. 1992. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267: 14998-15004.
12. LI, Y. et al. 1996. Molecular identity and distribution of advanced glycation endproducts receptors: Relationship of p60 to OST48 and p90 to 80K-H membrane proteins. Proc. Natl. Acad. Sci. USA 93: 11047-11052.
13. LI, Y.M., A.X. TAN & H. VLASSARA. 1995. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat. Med. 1: 1057-1061.
14. THORNALLEY, P.J. 1998. Cell activation by glycated proteins. Age receptors, receptor recognition factors and functional classification of AGEs. Cell. Mol. Biol. 44: 1013-1023.
15. GIARDINO, I., D. EDELSTEIN & M. BROWNLEE. 1994. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. J. Clin. Invest. 94: 110-117.
16. YOUSSEF, S. et al. 1999. Effect of diabetes and aminoguanidine therapy on renal advanced glycation endproduct binding. Kidney Int. 55: 907-916.
17. MCROBERT, E.A. et al. 2003. The amino terminal domains of ERM proteins bind advanced glycation endproducts: an interaction that may play a role in the development of diabetic complications. J. Biol. Chem. 278: 25783-25789.
18. HIRAO, M. et al. 1996. Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway. J. Cell Biol. 135: 37-51.
19. ORLANDO, R.A. et al. 2001. The glomerular epithelial cell anti-adhesion podocalyxin associates with the actin cytoskeleton through interactions with ezrin. J. Am. Soc. Nephrol. 12: 1589-1598.
20. SHAW, A.S. 2001. FERMing up the synapse. Immunity 15: 683-686.
21. BRETSCHER, A. 1989. Rapid phosphorylation and reorganization of ezrin and spectrin accompany morphological changes induced in A-431 cells by epidermal growth factor. J. Cell Biol. 108: 921-930.
22. 2-terminal domain inhibits the cell extension activity of the COOH-terminal domain. J. Cell Biol. 128: 1081-1093.
23. DOI, Y. et al. 1999. Normal development of mice and unimpaired cell adhesion/cell motility/actin-based cytoskeleton without compensatory up-regulation of ezrin or radixin in moesin gene knockout. J. Biol. Chem. 274: 2315-2321.
24. KRIEG, J. & T. HUNTER. 1992. Identification of the two major epidermal growth factor-induced tyrosine phosphorylation sites in the microvillar core protein ezrin. J. Biol. Chem. 267: 19258-19265.
25. CREPALDI, T. et al. 1997. Ezrin is an effector of HGF-mediated migration and morphogenesis in epithelial cells. J. Cell Biol. 138: 423-434.
26. SOMLO, S. & P. MUNDEL. 2000. Getting a foothold in nephrotic syndrome. Nat. Gen. 24: 333-335.
27. TAKEDA, T. et al. 2001. Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. J. Clin. Invest. 108: 289-301.
28. MIFSUD, S.A. et al. 2001. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 44: 878-882.
29. CORTES, P. et al. 2000. F-actin fiber distribution in glomerular cells: structural and functional implications. Kidney Int. 58: 2452-2461.
30. ZHOU, X. et al. 1995. High glucose alters actin assembly in glomerular mesangial and epithelial cells. Lab. Invest. 73: 372-383.
31. KIM, E.K. et al. 1992. Corneal endothelial cytoskeletal changes in F-actin with aging, diabetes and after cytochalasin exposure. Am. J. Ophthalmol. 114: 329-335.
32. + exchange inhibition. Circ. Res. 87: 1133-1140.
33. TSUKITA, S. et al. 1994. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J. Cell Biol. 126: 391-401.
34. TSUKITA, S. & S. YONEMURA. 1999. Cortical actin organization lessons from ERM (Ezrin/Radixin/Moesin) proteins. J. Biol. Chem. 274: 34507-34510.
35. HEISKA, L. et al. 1998. Association of ezrin with intracellular adhesion molecule-1 and -2 (ICAM-1 and ICAM-2): regulation by phosphatidylinositol 4,5-biphosphate. J. Biol. Chem. 273: 21893-21900.
36. TURUREN, O., T. WAHLSTROM & A. VAHERI. 1994. Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family. J. Cell Biol. 126: 1445-1453.
37. BRETSCHER, A., R. GARY & M. BERRYMAN. 1995. Soluble ezrin purified from placenta exists as stable monomers and elongated dimers with masked C-terminal ERM association domains. Biochemistry 34: 16830-16837.
38. SIMONS, P. et al. 1998. C-terminal threonine phosphorylation activates ERM proteins to link the cell's cortical bilayer to the cytoskeleton. Biochem. Biophys. Res. Commun. 253: 561-565.
39. GAUTREAU, A., D. LOUVARD & M. ARPIN. 2000. Morphogenic effects of ezrin require a phosphorylation-induced transition from oligomers to monomers at the plasma membrane. J. Cell Biol. 150: 193-203.
40. YAO, X., A. THIBODEAU & J.G. FORTE. 1993. Ezrin-calpain 1 interactions in gastric parietal cells. Am. J. Physiol. 265: C36-C46.
41. VLASSARA, H. et al. 1995. Identification of galectin-3 as a high affinity binding protein for advanced glycation endproducts (AGE): a new member of the AGE-receptor family. Mol. Med. 1: 634-646.
42. YANG, C.-W. et al. 1991. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts; relationship to macrophage receptor for glucose-modified proteins. J. Exp. Med. 174: 515-524.
43. RECZEK, D. & A. BRETSCHER. 1998. The carboxyl-terminal region of EBP50 binds to a site in the amino-terminal domain of ezrin that is masked in the dormant molecule. J. Biol. Chem. 273: 18452-18458.
44. ISHIKAWA, H. et al. 2001. Structural conversion between open and closed forms of radixin: low-angle shadowing electron microscopy. J. Mol. Biol. 310: 23371-23375.
45. SMITH, W.J. et al. 2003. Structure of the active FERM domain of ezrin: conformational and mobility changes identify keystone interactions. J. Biol. Chem. 278: 4949-4956.
46. EDWARDS, S.D. & N.H. KEEP. 2001. The 2.7 A crystal structure of the activated PERM domain of moesin: an analysis of structural changes on activation. Biochemistry 40: 7061-7068.
47. HAMADA, K. et al. 2000. Structural basis of the membrane-targeting and unmasking mechanisms of the radixin PERM domain. EMBO J. 19: 4449-4462.